Lesotho vs Nigeria: Statin use vs. average non-HDL cholesterol levels
Lesotho
2.5
in 2018
Nigeria
2.6
in 2018
Lesotho rank
190th
Nigeria rank
187th
Statin use vs. average non-HDL cholesterol levels over time
- Lesotho
- Nigeria
How they compare
Nigeria currently reports 2.6 against 2.5 in Lesotho, a difference of 0.1.
The two have swapped places 8 times across 39 shared years of data; in 1980 it was Nigeria ahead.
Lesotho ranks 190th and Nigeria ranks 187th of 191 countries.
Across the 4 decades both report, Lesotho averaged higher in 3 and Nigeria in 1.
Head to head by decade
| Decade | Lesotho | Nigeria | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.18 | 2.14 | 0.04 | Lesotho |
| 1990s | 2.34 | 2.26 | 0.08 | Lesotho |
| 2000s | 2.44 | 2.43 | 0.01 | Lesotho |
| 2010s | 2.5 | 2.57 | 0.0667 | Nigeria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Lesotho or Nigeria?
- Nigeria, at 2.6 against 2.5 in Lesotho as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Lesotho and Nigeria?
- 0.1, with Nigeria ahead.
- How many years of comparable data are there for Lesotho and Nigeria?
- 39 years are reported by both, from 1980 to 2018.
- How do Lesotho and Nigeria rank globally for statin use vs. average non-hdl cholesterol levels?
- Lesotho ranks 190th and Nigeria ranks 187th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.